Resultats de la cerca - Deborah M. Stephens

Refinar resultats
  1. 1
    NCCN Guidelines Update: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    NCCN Guidelines Update: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma per Deborah M. Stephens

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia

    How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia per Deborah M. Stephens, John C. Byrd

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736

    Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736 per Deborah M. Stephens, Hongli Li, Michael LeBlanc, Soham D. Puvvada, Daniel O. Persky, Jonathan W. Friedberg, Sonali M. Smith

    Publicat 2016
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis

    Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis per Adam S. Kittai, Ying Huang, Max J. Gordon, Nathan Denlinger, Agrima Mian, Lindsey Fitzgerald, Jennifer Bishop, Sarah Nagle, Deborah M. Stephens, Samantha Jaglowski, Brian T. Hill, Alexey V. Danilov

    Publicat 2020
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

    Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Smal... per William G. Wierda, Kathleen A. Dorritie, Javier Muñoz, Deborah M. Stephens, Scott R. Solomon, Heidi H. Gillenwater, Lucy Gong, Lin Yang, K. OGASAWARA, Jerill Thorpe, Tanya Siddiqi

    Publicat 2020
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies

    Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies per Jennifer A. Woyach, Deborah M. Stephens, Ian W. Flinn, Seema A. Bhat, Ronald E. Savage, Fang Chai, Sudharshan Eathiraj, Lindsey Granlund, Lyndsey Szuszkiewicz, Brian Schwartz, John C. Byrd

    Publicat 2019
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    A single‐institution retrospective cohort study of first‐line R‐<scp>EPOCH</scp> chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor

    A single‐institution retrospective cohort study of first‐line R‐<scp>EPOCH</scp> chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyoty... per Kerry A. Rogers, Ying Huang, Amy S. Ruppert, G. Salem, Deborah M. Stephens, Nyla A. Heerema, Leslie A. Andritsos, Farrukh T. Awan, John C. Byrd, Joseph M. Flynn, Kami J. Maddocks, Jeffrey A. Jones

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

    Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL per Tanya Siddiqi, Jacob D. Soumerai, Kathleen A. Dorritie, Deborah M. Stephens, Peter A. Riedell, Jon Arnason, Thomas J. Kipps, Heidi H. Gillenwater, Lucy Gong, Lin Yang, K. OGASAWARA, Jerill Thorpe, William G. Wierda

    Publicat 2021
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

    Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expa... per Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, Herbert Eradat, Danielle M. Brander, Michael Tees, Sameer A. Parikh, Tycel Phillips, Razi Ghori, Nishitha Reddy, Mohammed Z.H. Farooqui, John C. Byrd, Deborah M. Stephens

    Publicat 2022
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients

    Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients per Jennifer R. Brown, John C. Byrd, Paolo Ghia, Jeff P. Sharman, Peter Hillmen, Deborah M. Stephens, Clare Sun, Wojciech Jurczak, John M. Pagel, Alessandra Ferrajoli, Priti Patel, Lin Tao, Nataliya Kuptsova‐Clarkson, Javid J. Moslehi, Richard R. Furman

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

    Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib per Farrukh T. Awan, Anna Schuh, Jennifer R. Brown, Richard R. Furman, John M. Pagel, Peter Hillmen, Deborah M. Stephens, Jennifer A. Woyach, Елена Бибикова, Prista Charuworn, Melanie M. Frigault, Ahmed Hamdy, Raquel Izumi, Bolan Linghu, Priti Patel, Min Hui Wang, John C. Byrd

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Acalabrutinib in treatment-naive chronic lymphocytic leukemia

    Acalabrutinib in treatment-naive chronic lymphocytic leukemia per John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O’Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Stephen Devereux, Peter Hillmen, John M. Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, William G. Wierda

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma

    Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma per Deborah M. Stephens, Hongli Li, Heiko Schöder, David J. Straus, Craig H. Moskowitz, Michael LeBlanc, Lisa M. Rimsza, Nancy L. Bartlett, Andrew M. Evens, Ann S. LaCasce, Paul M. Barr, Michael V. Knopp, Eric D. Hsi, John P. Leonard, Brad S. Kahl, Sonali M. Smith, Jonathan W. Friedberg

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

    A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/... per Alexey V. Danilov, Michael Tees, Krish Patel, William G. Wierda, Manish R. Patel, Ian W. Flinn, Tahir Latif, Weiyun Z. Ai, Meghan C. Thompson, Michael Wang, Clare Sun, Deborah M. Stephens, Michael J. Thirman, Melissa Gessner, Johannes Wolff, Amanda Schwab, May Tan, Daniel C. Chan, Erin Meredith, Adrian Wiestner

    Publicat 2023
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

    The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model per Max J. Gordon, Andy Kaempf, Andrea Sitlinger, Geoffrey Shouse, Matthew Mei, Danielle M. Brander, Tareq Salous, Brian T. Hill, Hamood Alqahtani, Michael Y. Choi, Michael C. Churnetski, Jonathon B. Cohen, Deborah M. Stephens, Tanya Siddiqi, Xavier Rivera, Daniel O. Persky, Paul Wisniewski, Krish Patel, Mazyar Shadman, Byung Park, Alexey V. Danilov

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma

    A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma per Geoffrey Shouse, Andy Kaempf, Max J. Gordon, Andrew Artz, David Yashar, Audrey M. Sigmund, Gordon Smilnak, Steven M. Bair, Agrima Mian, Lindsey Fitzgerald, Amneet Bajwa, Samantha Jaglowski, Neil A. Bailey, Mazyar Shadman, Krish Patel, Deborah M. Stephens, Manali Kamdar, Brian T. Hill, Jordan Gauthier, Reem Karmali, Loretta J. Nastoupil, Adam S. Kittai, Alexey V. Danilov

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004

    Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004 per Tanya Siddiqi, David G. Maloney, Saad S. Kenderian, Danielle M. Brander, Kathleen A. Dorritie, Jacob D. Soumerai, Peter A. Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena K. Perna, Sherilyn A. Tuazon, San-San Ou, Neha Rane, William G. Wierda

    Publicat 2023
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001

    Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001 per Daniel O. Persky, Hongli Li, Deborah M. Stephens, Steven I. Park, Nancy L. Bartlett, Lode J. Swinnen, Paul M. Barr, Jerome D. Winegarden, Louis S. Constine, Thomas J. FitzGerald, John P. Leonard, Brad S. Kahl, Michael LeBlanc, Joo Y. Song, Richard I. Fisher, Lisa M. Rimsza, Sonali M. Smith, Thomas P. Miller, Jonathan W. Friedberg

    Publicat 2020
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD

    PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD per Bradley M. Haverkos, Diana Abbott, Mehdi Hamadani, Philippe Armand, Mary E.D. Flowers, Reid W. Merryman, Manali Kamdar, Abraham S. Kanate, Ayman Saad, Amitkumar Mehta, Siddhartha Ganguly, Timothy S. Fenske, Parameswaran Hari, Robert Lowsky, Leslie A. Andritsos, Madan Jagasia, Asad Bashey, Stacey Brown, Veronika Bachanová, Deborah M. Stephens, Shin Mineishi, Ryotaro Nakamura, Yi‐Bin Chen, Bruce R. Blazar, Jonathan A. Gutman, Steven M. Devine

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

    Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results per John C. Byrd, William G. Wierda, Anna Schuh, Stephen Devereux, Jorge Chaves, Jennifer R. Brown, Peter Hillmen, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, John M. Pagel, Jennifer A. Woyach, Kathleen A. Burke, Todd Covey, Michael Gulrajani, Ahmed Hamdy, Raquel Izumi, Melanie M. Frigault, Priti Patel, Wayne Rothbaum, Min Hui Wang, Susan O’Brien, Richard R. Furman

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: